Article
Biochemistry & Molecular Biology
Si-Yuan Zhu, Ding Ma, Zhi-Ming Shao, Ke-Da Yu
Summary: The study found that in patients with triple-negative breast cancer, the immune-inflamed tumor subtype may be associated with longer RFS in node-positive patients and pT2-3 stage tumor patients. However, in terms of treatment efficacy, there was no significant difference in RFS between the two regimens for either hot or cold tumor phenotypes.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Article
Oncology
B. Liu, L. Liu, J. Ran, N. Xie, J. Li, H. Xiao, X. Yang, C. Tian, H. Wu, J. Lu, J. Gao, X. Hu, M. Cao, Z. Shui, Z. -y. Hu, Q. Ouyang
Summary: This study compared the efficacy and safety of eribulin plus anlotinib versus eribulin monotherapy in patients with locally recurrent or metastatic breast cancer. The results showed that the combination therapy significantly improved progression-free survival and had higher rates of local control and objective response compared to eribulin alone, making it a viable treatment option for HER2-negative locally advanced or metastatic breast cancer.
Review
Oncology
Sreerenjini Lakshmi, Thomas A. Hughes, Sulochana Priya
Summary: Exosomes and their RNA have potential roles in breast cancer biology and treatment, participating in breast cancer tumorigenesis and progression through the transfer of miRNAs and LncRNAs. The diagnostic and therapeutic applications of exosomal miRNAs/LncRNAs in breast cancer have been highlighted in numerous publications.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Biochemical Research Methods
Xuanyi Wang, Zixuan Chai, Guizhi Pan, Youjin Hao, Bo Li, Ting Ye, Yinghong Li, Fei Long, Lixin Xia, Mingwei Liu
Summary: ExoBCD is the first well-corroborated knowledge base for exosomal studies of breast cancer, integrating a large number of annotation entries and exosomal molecules information, providing rich data on experimental biology and gene expression patterns.
BRIEFINGS IN BIOINFORMATICS
(2021)
Article
Medicine, General & Internal
Valentina Guarneri, Fara Braso-Maristany, Maria Vittoria Dieci, Gaia Griguolo, Laia Pare, Mercedes Marin-Aguilera, Federica Miglietta, Michele Bottosso, Carlo Alberto Giorgi, Paula Blasco, Oleguer Castillo, Patricia Galvan, Ana Vivancos, Patricia Villagrasa, Joel S. Parker, Charles M. Perou, PierFranco Conte, Aleix Prat
Summary: This study evaluated the predictive ability of HER2DX in early-stage HER2-positive/hormone receptor-positive breast cancer. The results showed that HER2DX scores were associated with the response to letrozole and dual HER2 blockade with trastuzumab and pertuzumab.
Article
Oncology
Birgitte V. Offersen, Jan Alsner, Hanne M. Nielsen, Erik H. Jakobsen, Mette H. Nielsen, Lars Stenbygaard, Anders N. Pedersen, Mette S. Thomsen, Esben Yates, Martin Berg, Ebbe L. Lorenzen, Ingelise Jensen, Mirjana Josipovic, Maj-Britt Jensen, Jens Overgaard
Summary: External-beam PBI is noninferior to WBI in terms of breast induration for patients with low-risk breast cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Pharmacology & Pharmacy
Adriana G. Quiroz-Reyes, Paulina Delgado-Gonzalez, Jose Francisco Islas, Juan Luis Delgado Gallegos, Javier Humberto Martinez Garza, Elsa N. Garza-Trevino
Summary: TRAIL is a promising strategy for tumor elimination, but cancer stem cells can easily develop evasion mechanisms for TRAIL-induced apoptosis.
Article
Medicine, Research & Experimental
Gregory Noel, Mireille Langouo Fontsa, Soizic Garaud, Pushpamali De Silva, Alexandre De Wind, Gert G. Van den Eynden, Roberto Salgado, Anais Boisson, Hanne Locy, Noemie Thomas, Cinzia Solinas, Edoardo Migliori, Celine Naveaux, Hugues Duvillier, Sophie Lucas, Ligia Craciun, Kris Thielemans, Denis Larsimont, Karen Willard-Gallo
Summary: This study found that T follicular helper (Tfh) cells in breast cancer play a key role in the formation of tertiary lymphoid structures (TLS), with active and functional Tfh TILs in TLS being associated with positive clinical outcomes in patients. The balance between functional Tfh TILs and functional T follicular regulatory (Tfr) TILs dictates the activity of tumor-associated TLS.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Immunology
Qing Peng, Tingyu Wen, Dongyang Liu, Suguo Wang, Xinting Jiang, Shiju Zhao, Gaozhong Huang
Summary: This study comprehensively analyzed DSN1 expression in different molecular subtypes or stages of breast cancer, and found that upregulation of DSN1 was strongly associated with poor prognosis and decreased survival in breast cancer. Significant differences in DSN1 expression were also observed in different pathological subtypes and stages of breast cancer.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Oncology
Lorenzo Gerratana, Masha Kocherginsky, Andrew A. Davis, Paolo D'Amico, Carolina Reduzzi, Fabio Puglisi, Massimo Cristofanilli
Summary: This study analyzed the stratification of circulating tumor cells (CTCs) using machine learning in breast cancer patients, explored factors associated with prognosis, and found a correlation between predicted CTCs and treatment effect, highlighting the importance of biomarker analysis in biomarker-driven drug development.
Article
Immunology
Xiangyu Sun, Xin Fu, Shouping Xu, Pengfei Qiu, Zhidong Lv, Mingke Cui, Qiang Zhang, Yingying Xu
Summary: This study investigated the expression of OLR1 in breast cancer tissues and its correlation with clinical outcomes, finding that OLR1 upregulation was associated with worse prognosis and tumor infiltration. Additionally, OLR1 may regulate immunity-related pathways, particularly macrophage polarization, affecting the survival of breast cancer patients.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Oncology
Qin Huo, Zhenwei Li, Siqi Chen, Juan Wang, Jiaying Li, Ni Xie
Summary: In this study, we found that VWCE expression was significantly lower in breast cancer tissues compared to normal tissues, and it was associated with subtypes and receptor statuses of breast cancer patients. VWCE expression was also correlated with the activation or inhibition of multiple oncogenic pathways, and with the immune infiltration levels of Th1 and M2 macrophages in breast cancer. These findings suggest that VWCE could be a potential prognostic biomarker and therapeutic target in breast cancer.
CANCER CELL INTERNATIONAL
(2021)
Review
Oncology
Maria Teresa Vietri, Giovanna D'Elia, Giuditta Benincasa, Giuseppe Ferraro, Gemma Caliendo, Giovanni Francesco Nicoletti, Claudio Napoli
Summary: This review discusses the DNA methylation changes potentially involved in breast cancer development and their potential clinical utility in diagnosis, prognosis, and therapy. The inactivation of tumor suppressor genes through promoter hypermethylation, detection of targeted and genome-wide DNA methylation changes through liquid-based assays, and the use of epigenetic drugs in combination with anticancer therapies show promise in personalized treatment strategies for breast cancer patients.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2021)
Article
Cell Biology
Torsten O. Nielsen, Samuel C. Y. Leung, Nazia Riaz, Anna M. Mulligan, Zuzana Kos, Anita Bane, Timothy J. Whelan
Summary: The LUMINA trial showed that in women aged 55 and above with low-risk luminal A breast cancer, very low local recurrence rate was observed when treated with breast-conserving surgery and endocrine therapy, supporting the safe omission of radiation. Ki67 is a practical, reproducible, and inexpensive biomarker that can identify low-risk luminal A breast cancers as potential candidates for radiation de-escalation.
Article
Oncology
Alexandre Prieur, Andrew Harper, Momtafin Khan, Berengere Vire, Dominique Joubert, Lea Payen, Karen Kopciuk
Summary: Circulating progastrin or hPG(80) can serve as a potential prognostic biomarker for breast cancer, as it is associated with survival outcomes. This study found that higher levels of hPG(80) at diagnosis are significantly associated with an increased risk of recurrence or death in women with breast cancer.